Search Science Hub

Science Hub is Novo Nordisk’s one-stop portal for all our scientific publications and clinical trials, congress materials and medical updates. Sign up to gain full access.

Welcome to Novo Nordisk Science Hub

Are you a healthcare professional?

EASD 2026 28 September - 2 October 2026

Major Adverse Cardiovascular Events in Adults With Type 2 Diabetes Escalating to Semaglutide 2.0 mg vs Switching to Tirzepatide

Authors :

Gang Fang¹; Chalak Muhammad¹; Caroline Swift¹; Josh Noone¹; Yuanjie Liang¹; Sherif Mehanna¹; Thomas P. Gunnarsson²; Kathryn Tierney³

Affiliations

View Details Hide Details

Download the poster (.pdf)

Keywords

Diabetes

Congress short oral presentation

GLP-1 RA

Semaglutide

RWE